Argonne National Laboratory and SourceTech Medical

A startup joint venture that helped to meet demand for radioactive seeds to treat prostate cancer. As recent as the late 1990′s patients waited approximately six months for radioactive seed treatment of prostate cancer. Today, they only wait a few days for radioactive seeds, in part due to the additional capacity provided by this joint venture. Argonne National Laboratory and SourceTech Medical collaborated, resulting in the launch of a successful and unique high-accuracy radioactive seed manufacturing process in a mere two years.